Endogenous Glucagon-like Peptide 1 Controls Endocrine Pancreatic Secretion and Antro-pyloro-duodenal Motility in Humans

Overview

Journal Gut

Specialty Gastroenterology

Date 2005 Jun 30

PMID 15985560

Citations 90

Authors

J Schirra

M Nicolaus

R Roggel

M Katschinski

M Storr

H J Woerle

B Goke

Affiliations

Soon will be listed here.

Abstract

Background: Exogenous use of the intestinal hormone glucagon-like peptide 1 (GLP-1) lowers glycaemia by stimulation of insulin, inhibition of glucagon, and delay of gastric emptying.

Aims: To assess the effects of endogenous GLP-1 on endocrine pancreatic secretion and antro-pyloro-duodenal motility by utilising the GLP-1 receptor antagonist exendin(9-39)amide (ex(9-39)NH2).

Methods: Nine healthy volunteers underwent four experiments each. In two experiments with and without intravenous infusion of ex(9-39)NH2 300 pmol/kg/min, a fasting period was followed by intraduodenal glucose perfusion at 1 and 2.5 kcal/min, with the higher dose stimulating GLP-1 release. Antro-pyloro-duodenal motility was measured by perfusion manometry. To calculate the incretin effect (that is, the proportion of plasma insulin stimulated by intestinal hormones) the glycaemia observed during the luminal glucose experiments was mimicked using intravenous glucose in two further experiments.

Results: Ex(9-39)NH2 significantly increased glycaemia during fasting and duodenal glucose. It diminished plasma insulin during duodenal glucose and significantly reduced the incretin effect by approximately 50%. Ex(9-39)NH2 raised plasma glucagon during fasting and abolished the decrease in glucagon at the high duodenal glucose load. Ex(9-39)NH2 markedly stimulated antroduodenal contractility. At low duodenal glucose it reduced the stimulation of tonic and phasic pyloric motility. At the high duodenal glucose load it abolished pyloric stimulation.

Conclusions: Endogenous GLP-1 stimulates postprandial insulin release. The pancreatic alpha cell is under the tonic inhibitory control of GLP-1 thereby suppressing postprandial glucagon. GLP-1 tonically inhibits antroduodenal motility and mediates the postprandial inhibition of antral and stimulation of pyloric motility. We therefore suggest GLP-1 as a true incretin hormone and enterogastrone in humans.

Citing Articles

Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus.

He X, Zhao W, Li P, Zhang Y, Li G, Su H Front Pharmacol. 2025; 15:1483792.

PMID: 39902077 PMC: 11788294. DOI: 10.3389/fphar.2024.1483792.

Bitarafan V, Anjom-Shoae J, Rezaie P, Fitzgerald P, Lange K, Horowitz M Diabetologia. 2024; .

PMID: 39690248 DOI: 10.1007/s00125-024-06344-9.

Physiology and Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal Motility.

Jalleh R, Marathe C, Rayner C, Jones K, Umapathysivam M, Wu T Endocrinology. 2024; 166(1).

PMID: 39568409 PMC: 11630531. DOI: 10.1210/endocr/bqae155.

The effects of gut microbiota on appetite regulation and the underlying mechanisms.

Yu M, Yu B, Chen D Gut Microbes. 2024; 16(1):2414796.

PMID: 39501848 PMC: 11542600. DOI: 10.1080/19490976.2024.2414796.

Is it necessary to stop glucagon-like peptide-1 receptor agonists prior to endoscopic procedure? A retrospective study.

Ghazanfar H, Javed N, Qasim A, Sosa F, Altaf F, Khan S World J Gastroenterol. 2024; 30(26):3221-3228.

PMID: 39086638 PMC: 11287410. DOI: 10.3748/wjg.v30.i26.3221.

References

Elahi D, Fukagawa N, Meneilly G, Sclater A, Minaker K, Habener J . The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept. 1994; 51(1):63-74. DOI: 10.1016/0167-0115(94)90136-8. View

Pfeiffer A, Schmidt T, Vidon N, Kaess H . Effect of ethanol on absorption of a nutrient solution in the upper human intestine. Scand J Gastroenterol. 1993; 28(6):515-21. DOI: 10.3109/00365529309098259. View

Wang Z, Wang R, Owji A, Smith D, Ghatei M, Bloom S . Glucagon-like peptide-1 is a physiological incretin in rat. J Clin Invest. 1995; 95(1):417-21. PMC: 295450. DOI: 10.1172/JCI117671. View

Fehmann H, Hering B, Wolf M, Brandhorst H, Brandhorst D, Bretzel R . The effects of glucagon-like peptide-I (GLP-I) on hormone secretion from isolated human pancreatic islets. Pancreas. 1995; 11(2):196-200. DOI: 10.1097/00006676-199508000-00014. View

Schirra J, Katschinski M, Weidmann C, Schafer T, Wank U, Arnold R . Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest. 1996; 97(1):92-103. PMC: 507066. DOI: 10.1172/JCI118411. View

Heller R, Aponte G . Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7--36) amide. Am J Physiol. 1995; 269(6 Pt 1):G852-60. DOI: 10.1152/ajpgi.1995.269.6.G852. View

Goke R, Larsen P, Mikkelsen J, Sheikh S . Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci. 1995; 7(11):2294-300. DOI: 10.1111/j.1460-9568.1995.tb00650.x. View

Orskov C, Poulsen S, Moller M, Holst J . Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes. 1996; 45(6):832-5. DOI: 10.2337/diab.45.6.832. View

Tseng C, Kieffer T, Jarboe L, Usdin T, Wolfe M . Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. J Clin Invest. 1996; 98(11):2440-5. PMC: 507699. DOI: 10.1172/JCI119060. View

10.

Schirra J, Kuwert P, Wank U, Leicht P, Arnold R, Goke B . Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men. Proc Assoc Am Physicians. 1997; 109(1):84-97. View

11.

Rodier G, Magous R, Mochizuki T, Martinez J, Nguyen D, Bali J . Effect of glicentin, oxyntomodulin and related peptides on isolated gastric smooth muscle cells. Pflugers Arch. 1997; 434(6):729-34. DOI: 10.1007/s004240050458. View

12.

Imeryuz N, Yegen B, Bozkurt A, Coskun T, Villanueva-Penacarrillo M, Ulusoy N . Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol. 1997; 273(4):G920-7. DOI: 10.1152/ajpgi.1997.273.4.G920. View

13.

Nauck M, Niedereichholz U, Ettler R, Holst J, Orskov C, Ritzel R . Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997; 273(5):E981-8. DOI: 10.1152/ajpendo.1997.273.5.E981. View

14.

Schirra J, Leicht P, Hildebrand P, Beglinger C, Arnold R, Goke B . Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1(7-36)amide in non-insulin dependent diabetes mellitus. J Endocrinol. 1998; 156(1):177-86. DOI: 10.1677/joe.0.1560177. View

15.

Schirra J, Sturm K, Leicht P, Arnold R, Goke B, Katschinski M . Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J Clin Invest. 1998; 101(7):1421-30. PMC: 508720. DOI: 10.1172/JCI1349. View

16.

Anvari M, Paterson C, Daniel E, McDonald T . Effects of GLP-1 on gastric emptying, antropyloric motility, and transpyloric flow in response to a nonnutrient liquid. Dig Dis Sci. 1998; 43(6):1133-40. DOI: 10.1023/a:1018863716749. View

17.

Tolessa T, Gutniak M, Holst J, Efendic S, Hellstrom P . Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig Dis Sci. 1998; 43(10):2284-90. DOI: 10.1023/a:1026678925120. View

18.

Wettergren A, Wojdemann M, Holst J . Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol. 1998; 275(5):G984-92. DOI: 10.1152/ajpgi.1998.275.5.G984. View

19.

Edwards C, Todd J, Mahmoudi M, Wang Z, Wang R, Ghatei M . Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes. 1999; 48(1):86-93. DOI: 10.2337/diabetes.48.1.86. View

20.

Kolligs F, Fehmann H, Goke R, Goke B . Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes. 1995; 44(1):16-9. DOI: 10.2337/diab.44.1.16. View